609 results match your criteria Small Cell Carcinoma of the Prostate


Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate.

Can Urol Assoc J 2022 Jun 9. Epub 2022 Jun 9.

Department of Medical Oncology, BC Cancer - Victoria, Victoria, BC, Canada.

Introduction: Unresectable and metastatic small cell carcinoma of the prostate (SCPC) is a rare and aggressive disease that is under-represented in clinical trials. We carried out a retrospective chart review of metastatic or unresectable SCPC patients at British Columbia (BC) Cancer centers, studying diagnosis and treatment patterns.

Methods: Drug dispensing records from the six BC Cancer centers were obtained from 2002- 2017. Read More

View Article and Full-Text PDF

Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study.

BMC Med 2022 06 6;20(1):203. Epub 2022 Jun 6.

Department of Biostatistics, School of Public Health, Nanjing Medical University, 101 Longmian Avenue, Nanjing, 211166, Jiangsu, China.

Background: Body mass index (BMI) has been found to be associated with a decreased risk of non-small cell lung cancer (NSCLC); however, the effect of BMI trajectories and potential interactions with genetic variants on NSCLC risk remain unknown.

Methods: Cox proportional hazards regression model was applied to assess the association between BMI trajectory and NSCLC risk in a cohort of 138,110 participants from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. One-sample Mendelian randomization (MR) analysis was further used to access the causality between BMI trajectories and NSCLC risk. Read More

View Article and Full-Text PDF

Paraneoplastic Evans Syndrome in a Patient With Prostate Cancer With Small Cell Transformation.

Cureus 2022 Apr 26;14(4):e24505. Epub 2022 Apr 26.

Hematology and Oncology, Marshall University Joan C. Edwards School of Medicine, Huntington, USA.

Paraneoplastic syndromes are defined as tumor-associated indirect systemic effects. Prostate cancer-associated paraneoplastic syndromes typically have endocrine, neurologic, and dermatologic manifestations. Reports have suggested up to 70% of metastatic prostate cancers manifest as paraneoplastic entities. Read More

View Article and Full-Text PDF

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.

J Immunother Cancer 2022 Jun;10(6)

Department of Pathology and Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA

Background: Tumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune responses in cancer and are generally associated with favorable prognosis. However, the relationships between TILs subsets and their spatial arrangement with clinical benefit from immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) remains less explored.

Methods: We used multiplexed quantitative immunofluorescence panels to determine the association of major TILs subpopulations, CD8 cytotoxic T cells, CD4 helper T cells and CD20 B cells, and T cell exhaustion markers, programmed cell death protein-1 (PD-1),lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin mucin-3 (TIM-3) with outcomes in a multi-institutional cohort of baseline tumor samples from 179 patients with NSCLC treated with ICI. Read More

View Article and Full-Text PDF

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.

J Immunother Cancer 2022 May;10(5)

Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway.

Background: Therapeutic cancer vaccines represent a promising approach to improve clinical outcomes with immune checkpoint inhibition. UV1 is a second generation telomerase-targeting therapeutic cancer vaccine being investigated across multiple indications. Although telomerase is a near-universal tumor target, different treatment combinations applied across indications may affect the induced immune response. Read More

View Article and Full-Text PDF

Male Breast Metastasis: A Case of Treatment-Emergent Neuroendocrine Prostate Cancer.

Cureus 2022 Apr 19;14(4):e24283. Epub 2022 Apr 19.

Internal Medicine, Hospital Prof. Doutor Fernando Fonseca, Amadora, PRT.

Treatment-emergent transformed neuroendocrine prostate cancer (NEPC) is a highly aggressive type of prostate cancer that may arise from typical adenocarcinoma of the prostate, which is associated with rapidly progressive disease involving visceral sites and refractoriness to hormonal therapy. We present the case of a 74-year old male with a known history of stable prostate adenocarcinoma treated with transurethral prostate resection, local radiotherapy (RT), and androgen deprivation therapy (ADT) in 2020 who presented to the emergency room with complaints of shoulder and anterior chest pain, dyspnoea, and fatigue. Upon examination, a solid, adherent breast mass and infra-clavicular adenopathy were palpable. Read More

View Article and Full-Text PDF

Genetic variants in DDO and PEX5L in peroxisome-related pathways predict non-small cell lung cancer survival.

Mol Carcinog 2022 Jul 3;61(7):619-628. Epub 2022 May 3.

Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.

Peroxisomes play a role in lipid metabolism and regulation of reactive oxygen species, but its role in development and progression of non-small cell lung cancer (NSCLC) is not well understood. Here, we investigated the associations between 9708 single-nucleotide polymorphisms (SNPs) in 113 genes in the peroxisome-related pathways and survival of NSCLC patients from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) and the Harvard Lung Cancer Susceptibility (HLCS) study. In 1185 NSCLC patients from the PLCO trial, we found that 213 SNPs were significantly associated with NSCLC overall survival (OS) (p ≤ 0. Read More

View Article and Full-Text PDF

Expression and prognostic analyses of the significance of STEAP1 and STEAP2 in lung cancer.

World J Surg Oncol 2022 Mar 28;20(1):96. Epub 2022 Mar 28.

Department of Thoracic Surgery, Heze Municipal Hospital, Heze, 274031, Shandong, China.

Purpose: Lung cancer is the leading cause of cancer-related mortality. STEAP1 and STEAP2 are overexpressed in various cancers. The purpose of this study was to evaluate the expression and prognostic value of STEAP1 and STEAP2 in patients with lung cancer. Read More

View Article and Full-Text PDF

Combination therapy with radiation and hyperthermia-induced clinical complete response of small cell carcinoma of prostate.

IJU Case Rep 2022 Mar 14;5(2):113-116. Epub 2022 Jan 14.

Department of Nephro-urology Graduate School of Medical Sciences Nagoya City University Nagoya Japan.

Introduction: Small cell carcinoma of the prostate has a poor prognosis even with standard systemic chemotherapy. We report a case, in which combination therapy with radiation and hyperthermia-induced clinical complete response.

Case Presentation: An 87-year-old man complaining of dysuria was referred to our hospital. Read More

View Article and Full-Text PDF

Small-cell carcinoma of the prostate with negative CD56, NSE, Syn, and CgA indicators: A case report.

World J Clin Cases 2022 Feb;10(5):1630-1638

Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Kunming 650000, Yunnan Province, China.

Background: Small-cell carcinoma of the prostate (SCCP) is a clinically rare malignant tumor, accounting for < 1% of all prostate tumors. However, negativity for all SCCP neuroendocrine markers is rare. Herein, we report a case of SCCP with completely negative neuroendocrine markers and explore its clinicopathologic features, thus improving the understanding of its clinical diagnosis and management. Read More

View Article and Full-Text PDF
February 2022

RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures.

Cancer Cell Int 2022 Feb 2;22(1):54. Epub 2022 Feb 2.

Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany.

Background: Canine prostate adenocarcinoma (PAC) and transitional cell carcinoma (TCC) are typically characterized by metastasis and chemoresistance. Cell lines are important model systems for developing new therapeutic strategies. However, as they adapt to culturing conditions and undergo clonal selection, they can diverge from the tissue from which they were originally derived. Read More

View Article and Full-Text PDF
February 2022

Diagnostic and Therapeutic Challenges in a Patient with Synchronous Very High-Risk Prostate Adenocarcinoma and Anal Carcinoma.

Curr Oncol 2022 01 15;29(1):377-382. Epub 2022 Jan 15.

Veterans Affairs New York Harbor Healthcare System, State University of New York-Downstate Medical Center, New York, NY 11209, USA.

A 79-year-old HIV-negative Caucasian man with a medical history of smoking 20 pack-years (quit 40 years prior), early-stage non-small cell lung cancer status post-lobectomy 13 years earlier at an outside hospital without evidence of recurrence, and benign prostatic hypertrophy was diagnosed with synchronous very high-risk prostate adenocarcinoma and early-stage anal basaloid squamous cell carcinoma. He proceeded to undergo concurrent treatment for these tumors, consisting of androgen deprivation therapy, external beam radiation therapy, and a brachytherapy boost for the prostate adenocarcinoma; for the anal carcinoma, he was treated with definitive chemoradiation. Over 3. Read More

View Article and Full-Text PDF
January 2022

Rare Case of Small Cell Metastatic Prostatic Adenocarcinoma, Properly Staged by 68Ga-PSMA PET/CT Scan.

Clin Nucl Med 2022 Mar;47(3):e259-e261

From the Nuclear Medicine Research Center.

Abstract: Small cell carcinoma (SCC) of the prostate is a very rare entity and one of most aggressive neuroendocrine malignancies of prostate. We present a 60-year-old man with pathology-proven prostatic SCC by transrectal biopsy with ultrasonography guidance and Gleason score of 5 + 5. He was referred to perform 68Ga-PSMA PET/CT scan for staging. Read More

View Article and Full-Text PDF

Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies.

Pathol Res Pract 2022 Jan 2;229:153731. Epub 2021 Dec 2.

Department of Pathology, Kanagawa Cancer Center, 2-3-2, Nakao, Asahi-Ku, Yokohama, Kanagawa 241-8515, Japan; Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2, Nakao, Asahi-Ku, Yokohama, Kanagawa 241-8515, Japan.

Differentiating small cell neuroendocrine (NE) carcinoma (SCNC) of the prostate from adenocarcinoma with NE differentiation based on morphological features alone sometimes can be challenging. Given that treatment strategies vary depending on histological type, an accurate diagnosis is critical. This study aimed to identify the accurate diagnostic factors for SCNC of the prostate. Read More

View Article and Full-Text PDF
January 2022

[Incidental prostate cancer: A clinicopathological study].

Zhonghua Nan Ke Xue 2021 Feb;27(2):145-149

Department of Urology, Drum Tower Hospital Affiliated to Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China.

Objective: To investigate the clinicopathological characteristics and prognosis of incidental prostate cancer (PCa).

Methods: We retrospectively analyzed the clinical data and pathological characteristics of 96 cases of incidental PCa in 580 patients undergoing radical cystectomy and followed them up for prognosis.

Results: The incidence rate of incidental PCa was 16. Read More

View Article and Full-Text PDF
February 2021

[Diagnosis and treatment of small cell neuroendocrine carcinoma of the prostate].

Zhonghua Nan Ke Xue 2021 Mar;27(3):219-225

Department of Urology, The Affected Hospital of Guilin Medical College, Guilin, Guangxi 541000, China.

Objective: To explore the clinical manifestations, pathological features and treatment of small cell neuroendocrine carcinoma of the prostate (SCPCa).

Methods: We reported 1 case of SCPCa treated in Jinan People's Hospital and analyzed the clinical data on another 57 cases reported in China.

Results: Of the total number of cases, 52 (91. Read More

View Article and Full-Text PDF

Case Report: Systemic Treatment and Serial Genomic Sequencing of Metastatic Prostate Adenocarcinoma Progressing to Small Cell Carcinoma.

Front Oncol 2021 27;11:732071. Epub 2021 Sep 27.

Department of Bioinformatics, Center for Translational Medicine, Second Military Medical University, Shanghai, China.

Small cell carcinoma (SCC)/neuroendocrine prostate cancer (NEPC) is a rare and highly aggressive subtype of prostate cancer associated with an AR(androgen receptor)-null phenotype and visceral metastases. This study presents a 44-year-old man originally diagnosed with metastatic hormone-sensitive prostatic adenocarcinoma. After 6-month androgen deprivation therapy (ADT) combined with docetaxel, the patient developed paraplegia. Read More

View Article and Full-Text PDF
September 2021

Genetic Variants of and Are Associated With Risk of Non-Small Cell Lung Cancer.

Front Oncol 2021 15;11:709829. Epub 2021 Sep 15.

Department of Radiology, Duke University Medical Center, Durham, NC, United States.

Background: Single nucleotide polymorphisms (SNPs) are often associated with distinct phenotypes in cancer. The present study investigated associations of cancer risk and outcomes with SNPs discovered by whole exome sequencing of normal lung tissue DNA of 15 non-small cell lung cancer (NSCLC) patients, 10 early stage and 5 advanced stage.

Methods: DNA extracted from normal lung tissue of the 15 NSCLC patients was subjected to whole genome amplification and sequencing and analyzed for the occurrence of SNPs. Read More

View Article and Full-Text PDF
September 2021

Mismatched Lesions on 18F-FDG PET and 18F-Fluciclovine PET Images in a Patient With Metastatic Prostate Small Cell Carcinoma.

Clin Nucl Med 2022 Mar;47(3):255-257

Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Abstract: A 65-year-old man with fluciclovine-avid metastatic prostate small cell carcinoma with prostate-specific antigen (PSA) 19.4 ng/mL at diagnosis underwent system therapy and subsequent surgery and achieved hormonal response with PSA <0.1 ng/mL. Read More

View Article and Full-Text PDF

Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate.

Eur Urol Open Sci 2021 Jan 3;23:30-33. Epub 2021 Jan 3.

Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah.

Primary squamous cell carcinoma is a rare, aggressive disease with historically poor outcomes and no established treatment guidelines. Case reports are limited but describe multiple treatment approaches. Seeking to identify practice patterns and treatment outcomes, we used the US National Cancer Data Base to identify 66 males with locoregional primary squamous cell carcinoma of the prostate treated with surgery, chemotherapy, and/or radiotherapy between 2004 and 2015. Read More

View Article and Full-Text PDF
January 2021

Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells.

Oncol Lett 2021 Jul 24;22(1):546. Epub 2021 May 24.

Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido 060-8543, Japan.

Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) has emerged as an ideal target in cancer therapeutics. However, the functions of STEAP1 in liver cancer remain unexplored. The current study aimed to characterize the biological roles of STEAP1 in liver cancer. Read More

View Article and Full-Text PDF

Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.

Prostate 2021 09 12;81(13):938-943. Epub 2021 Jul 12.

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.

Introduction: Chemotherapy in combination with immunotherapy has a proven survival benefit compared to chemotherapy alone in extensive stage small cell lung cancer (SCLC) and is the new standard of care. Since extrapulmonary small cell carcinomas (SCCs) are less common, treatment paradigms are reasonably extrapolated from SCLC regimens. We examined our institution's experience utilizing the combination of chemotherapy and immunotherapy (as used in SCLC) for SCC and neuroendocrine carcinoma of the prostate. Read More

View Article and Full-Text PDF
September 2021

Neuroendocrine carcinoma of prostate presenting with ascites.

J Cancer Res Ther 2021 Apr-Jun;17(2):577-579

Department of Surgery, Maulana Azad Medical College, New Delhi, India.

Prostate cancer is a very common cause of morbidity and mortality in India. The commonest type of prostate carcinoma is adenocarcinoma, most of them are confined to prostate at the time of presentation. Bone is the preferred site for metastasis. Read More

View Article and Full-Text PDF
November 2021

Genetic variants of CHEK1, PRIM2 and CDK6 in the mitotic phase-related pathway are associated with nonsmall cell lung cancer survival.

Int J Cancer 2021 09 10;149(6):1302-1312. Epub 2021 Jun 10.

Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.

The mitotic phase is a vital step in cell division and may be involved in cancer progression, but it remains unclear whether genetic variants in mitotic phase-related pathways genes impact the survival of these patients. Here, we investigated associations between 31 032 single nucleotide polymorphisms (SNPs) in 368 mitotic phase-related pathway genes and overall survival (OS) of patients with nonsmall cell lung cancer (NSCLC). We assessed the associations in a discovery data set of 1185 NSCLC patients from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and validated the findings in another data set of 984 patients from the Harvard Lung Cancer Susceptibility Study. Read More

View Article and Full-Text PDF
September 2021

Large-cell neuroendocrine tumor of the prostate: a case report and review of the literature.

J Med Case Rep 2021 May 7;15(1):254. Epub 2021 May 7.

Urology Department, René Dubos Hospital, Pontoise, France.

Background: Primitive neuroendocrine prostate neoplasms are rarely reported. This entity comprises carcinoïd tumors and poorly differentiated neuroendocrine tumors, mainly those of the small-cell type. Large-cell-type primitive tumors are exceptional, and only nine cases are reported in the literature. Read More

View Article and Full-Text PDF

Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases.

Diagn Pathol 2021 Apr 23;16(1):35. Epub 2021 Apr 23.

Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, 14642, USA.

Background: Small cell neuroendocrine carcinoma of the prostate (SCNECP) is a rare, aggressive subtype of prostate carcinoma. Most SCNECP arise from conventional prostate adenocarcinoma (CPAC) treated with androgen deprivation therapy (ADT).

Case Presentations: We identified four cases of CPAC treated with ADT, which evolved to SCNECP with liver metastasis. Read More

View Article and Full-Text PDF

Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.

Prostate 2021 06 13;81(8):469-477. Epub 2021 Apr 13.

Department of Pathology, LAC+USC and Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Background: Neuroendocrine prostatic carcinoma (NEPC) is uncommon. The pathogenesis, clinical association, and clinical implications of this disease are still evolving.

Methods: Clinicopathologic, immunohistochemical and genomic studies were used to investigate the incidence of NEPC in various clinicopathologic settings and the expression of various biomarkers in NEPC and non-NEPC as well as small cell NEPC. Read More

View Article and Full-Text PDF

Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms.

Precis Clin Med 2021 Mar 28;4(1):25-34. Epub 2021 Jan 28.

Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.

Prostate cancer (PCa) is a common cause of cancer-related mortality in men worldwide. Although most men are diagnosed with low grade, indolent tumors that are potentially curable, a significant subset develops advanced disease where hormone therapy is required to target the androgen receptor (AR). Despite its initial effect, hormone therapy eventually fails and the tumor progresses to lethal stages even through continued inhibition of AR. Read More

View Article and Full-Text PDF

Primary Neuroendocrine Tumor of the Scrotum: An Uncommon Site for a Rare Tumor.

J Investig Med High Impact Case Rep 2021 Jan-Dec;9:23247096211008717

SUNY Upstate Medical University, Syracuse, NY, USA.

Neuroendocrine tumors (NETs) are a heterogeneous group of tumors developing from neural crest cells, with numerous sites of origin, commonly the gastrointestinal and genitourinary tracts. NETs of the genitourinary tract are more common in women. Small cell carcinoma of the prostate or testicular carcinoid are the NETs in male. Read More

View Article and Full-Text PDF
October 2021

LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer.

Biomed Res Int 2021 26;2021:5561569. Epub 2021 Feb 26.

Department of Dermatology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China.

Lung cancer has a higher incidence rate and mortality rate than all other cancers. Early diagnosis and treatment of lung cancer remain a major challenge, and the 5-year survival rate of its patients is only 15%. Basic and clinical research, especially the discovery of biomarkers, is crucial for improving the diagnosis and treatment of lung cancer patients. Read More

View Article and Full-Text PDF